| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016867715 |
| P356 | DOI | 10.1038/CGT.2012.62 |
| P698 | PubMed publication ID | 22996742 |
| P50 | author | Valentina Gatta | Q57123026 |
| P2093 | author name string | E Gambini | |
| L Menotti | |||
| P Malatesta | |||
| E Reisoli | |||
| I Appolloni | |||
| M Barilari | |||
| P2860 | cites work | Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma | Q48135134 |
| PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. | Q48791387 | ||
| Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). | Q54242436 | ||
| Resistance to HSV-1 in the mouse is governed by two major, independently segregating, non-H-2 loci | Q54551037 | ||
| Gene therapy and targeted toxins for glioma | Q57006162 | ||
| Role of p53 in HER2-induced proliferation or apoptosis | Q73693478 | ||
| Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma | Q84906858 | ||
| Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver | Q24633957 | ||
| HMGB1 mediates endogenous TLR2 activation and brain tumor regression | Q27307459 | ||
| Six3 controls the neural progenitor status in the murine CNS | Q28507238 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival | Q30954768 | ||
| Herpes simplex virus oncolytic therapy for pediatric malignancies | Q33713824 | ||
| PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2 | Q33715843 | ||
| Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas | Q33809397 | ||
| Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. | Q34343768 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. | Q34546483 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors | Q35051285 | ||
| PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo | Q35080265 | ||
| A potential role for CXCR3 chemokines in the response to ocular HSV infection | Q35158048 | ||
| Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells | Q35214798 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses | Q35837026 | ||
| Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma | Q35939421 | ||
| Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. | Q36982110 | ||
| Re-evaluating natural resistance to herpes simplex virus type 1. | Q37492787 | ||
| New insights on adenovirus as vaccine vectors | Q37513550 | ||
| Rethinking herpes simplex virus: the way to oncolytic agents | Q37882608 | ||
| The molecular basis of herpesviruses as oncolytic agents | Q37899225 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin | Q39752828 | ||
| OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma | Q39866378 | ||
| Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. | Q39953338 | ||
| Genetics of natural resistance to herpesvirus infections in mice | Q39958787 | ||
| Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. | Q40117079 | ||
| Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF-induced oligodendroglioma | Q44146016 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 788-795 | |
| P577 | publication date | 2012-09-21 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice | |
| P478 | volume | 19 |
| Q38714321 | A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells |
| Q38120594 | C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview |
| Q36142487 | Designing Herpes Viruses as Oncolytics |
| Q91521080 | Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model |
| Q56378150 | HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses |
| Q33896979 | High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus |
| Q38348844 | Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? |
| Q59793764 | Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins |
| Q26998111 | Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy |
| Q38845078 | Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity |
| Q34574879 | Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. |
| Q38950892 | Retargeting of herpes simplex virus (HSV) vectors |
| Q36544212 | Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases |
Search more.